TLDR Adding estrogen increased bone mass in a transsexual man undergoing hormone therapy.
A 31-year-old transsexual male undergoing male-to-female transition experienced significant changes in bone mass during hormone therapy. Initially treated with cyproterone acetate (100 mg/day) for 30 months, his bone mass decreased by 5% per year, leading to high turnover osteoporosis. However, after adding oral oestradiol valerate (2 mg/day), his bone mass increased by 4% per year. This study highlighted the crucial role of sex hormones, including oestrogens, in maintaining bone mass in males, demonstrating their anabolic effects on bone.
166 citations,
October 2018 in “Endocrine Reviews” Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.
10 citations,
May 2009 in “Sexual and Relationship Therapy” The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.
October 2022 in “Springer eBooks” The document concludes that personalized hormonal treatments are important for transgender individuals and more research is needed for non-binary treatments.
88 citations,
September 2003 in “Clinical endocrinology” Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
10 citations,
January 2015 in “Przeglad Menopauzalny” Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.
